CBD Side Effects and Genetics: Why CBD Causes Diarrhea, Drowsiness, or Brain Fog for Some People

You tried CBD oil for anxiety, or sleep, or chronic pain. Instead of the calm that everyone on the internet promised, you got diarrhea. Or brain fog. Or you slept for twelve hours and woke up groggy. Your friend takes the same product — same brand, same dose — and feels genuinely relaxed with no side effects.

This is not about product quality. It is not about the brand, the extraction method, or whether you took it with food. The most likely explanation is that your liver processes CBD differently than your friend's, and the difference is written in your DNA.

How Your Body Metabolizes CBD

When you take CBD orally, it passes through your digestive system and into your liver before reaching your bloodstream — a process called first-pass metabolism. In the liver, enzymes from the cytochrome P450 family break CBD down into metabolites that are eventually eliminated from your body.

Two enzyme families do most of the work:

• CYP3A4 and CYP3A5 — the CYP3A subfamily is the primary metabolic pathway for CBD. These enzymes handle the largest share of CBD clearance. CYP3A4 is the dominant enzyme in most people, but CYP3A5 contributes meaningfully when it is functional.
• CYP2C19 — this is a secondary pathway. When the CYP3A route has reduced capacity, more CBD gets processed through CYP2C19 instead. CYP2C19 converts CBD to 7-OH-CBD, the primary active metabolite, which is pharmacologically active and associated with both therapeutic effects and side effects.

Think of it like a highway system. CYP3A is the main highway. CYP2C19 is an alternate route. If the main highway is partially closed (due to genetic variants that reduce CYP3A5 activity), more traffic gets diverted to the alternate route — and the metabolite profile changes.

The Gene-Gene Interaction: CYP3A5 + CYP2C19

A 2026 clinical study by Etkins et al., published in Clinical and Translational Science, identified a specific gene-gene interaction that dramatically increases CBD side effect risk. The key finding:

Participants with CYP3A5 poor metabolizer status combined with CYP2C19 intermediate or normal metabolizer status experienced diarrhea at a rate of 39% — compared to just 7% in other genotype combinations. That is a 5.6-fold difference in GI side effect risk based entirely on genotype.

Here is why this combination is problematic:

1. CYP3A5 is reduced or absent. In people with CYP3A5 poor metabolizer genotypes, the main CBD clearance pathway has reduced capacity. This is actually the majority of people of European descent — about 80–90% carry CYP3A5*3/*3, the non-functional genotype.
2. CYP2C19 picks up the slack. With CYP3A5 reduced, more CBD is metabolized through CYP2C19. If CYP2C19 is functional (intermediate or normal metabolizer), it efficiently converts the diverted CBD into 7-OH-CBD.
3. 7-OH-CBD accumulates. The excess production of this active metabolite through the CYP2C19 pathway is associated with gastrointestinal adverse events — particularly diarrhea, but also nausea and abdominal discomfort.

The critical insight is that neither gene alone predicts the side effect risk. CYP3A5 poor metabolizer status on its own is common and does not necessarily cause problems if CYP2C19 is also reduced. And CYP2C19 normal metabolizer status is perfectly fine if CYP3A5 is functional. It is the specific combination — one pathway down, the other up — that creates the elevated risk.

What This Means in Practice

If you carry the dual-risk genotype (CYP3A5 poor metabolizer + CYP2C19 intermediate or normal metabolizer), several things change about how CBD affects your body:

• Higher peak blood levels of 7-OH-CBD. The active metabolite reaches higher concentrations than it would in someone with functional CYP3A5, because the metabolic pathway is altered.
• Slower overall CBD clearance. With one major metabolic pathway reduced, total clearance time increases. This means each dose lingers longer, and effects (both therapeutic and adverse) may be more pronounced.
• Dose-dependent side effects at lower doses. What is a well-tolerated dose for someone with normal metabolism may produce side effects in someone with the dual-risk genotype. The 25mg dose that your friend tolerates fine may be functionally equivalent to a much higher dose in your body.
• Cumulative effects with regular use. If you take CBD daily and clear it slowly, blood levels can build up over time. Side effects that were absent on day one may appear on day five or ten.

This also explains why CBD side effects are so inconsistent across anecdotal reports. The same product at the same dose produces dramatically different metabolite profiles depending on the user's genotype — and most users have no idea what their genotype is.

Other Genetic Factors in Cannabis Metabolism

CYP3A5 and CYP2C19 are the most important genes for CBD specifically, but other genetic factors matter for cannabis products more broadly:

• CYP1A2 — this enzyme is relevant for smoked or vaped cannabis. Compounds in cannabis smoke (not CBD itself) can induce or inhibit CYP1A2, affecting the metabolism of other medications you take — including caffeine, clozapine, and certain antidepressants.
• CYP2C9 — this is the primary enzyme for THC metabolism. CYP2C9 poor metabolizers clear THC more slowly, which may result in more intense and longer-lasting psychoactive effects. If you find that THC edibles hit you harder than expected, CYP2C9 may be a factor.
• CYP3A4 — while genetically less variable than CYP3A5, CYP3A4 activity can be significantly affected by drug-drug interactions. If you take other medications that inhibit CYP3A4 (such as ketoconazole, clarithromycin, or certain HIV medications), CBD clearance slows further.

For a broader look at how your genetics affect cannabis and CBD response, including THC sensitivity and the endocannabinoid system, see our guide on cannabis genetics from 23andMe data.

What to Do If You Suspect Genetic Sensitivity

If you have experienced GI side effects, excessive drowsiness, or brain fog from CBD — especially at doses that others tolerate well — here are practical steps:

• Start with a lower dose. If the standard recommended dose (typically 25–50mg) causes problems, try 10–15mg and see how you respond. Genetic slow metabolizers may need significantly lower doses to avoid side effects.
• Space doses further apart. If you are clearing CBD more slowly, daily dosing can lead to accumulation. Every other day dosing may produce therapeutic effects without triggering GI symptoms.
• Consider sublingual over oral. Sublingual administration (holding oil under the tongue) partially bypasses first-pass liver metabolism, which may reduce the metabolite imbalance caused by the CYP3A5/CYP2C19 interaction.
• Check your other medications. If you take drugs that inhibit CYP3A4 or CYP2C19, the interaction may compound your genetic predisposition. Discuss this with your pharmacist.
• Get your genotype tested. Instead of guessing, confirm whether you carry the dual-risk genotype.

Clinical Reference

Etkins AE et al. CYP3A and CYP2C19 genotypes impact cannabidiol safety and steady-state pharmacokinetics. Clin Transl Sci. 2026;19:e70455. PMID: 41451876.